Key result
LPL 447X and APOE ε3/ε3 genotypes are linked to ~34% lower diabetic nephropathy risk.
Why the study?
The association of LPL S447X, APOE exon 4, and APOC3 -455T>C polymorphisms with susceptibility to diabetic nephropathy in type 2 diabetes was unclear.
Are LPL S447X, APOE exon 4, and APOC3 -455T>C polymorphisms associated with the susceptibility to diabetic nephropathy in patients with type 2 diabetes?
Case-Control (n=766)
Are LPL S447X, APOE exon 4, and APOC3 -455T>C polymorphisms associated with the susceptibility to diabetic nephropathy in patients with type 2 diabetes?
Odds Ratio: 0.66
Absolute Event Rate: 18.6% vs 25.6%
p-value: p=0.02
Specific polymorphisms in lipid-regulating genes (LPL, APOE, APOC3) and their interactions are associated with a reduced risk of diabetic nephropathy in type 2 diabetes.
Diabetic nephropathy (DN) is the leading cause of end-stage renal disease. In DN patients, triglyceride (TG) level is elevated and lipoprotein lipase (LPL) activity, which hydrolyzes TG, is decreased. The LPL S447X and apolipoprotein E (APOE) exon 4 polymorphisms affect TG levels, and the APOC3 -455T>C polymorphism affects LPL activity. Our aim was to examine the association of these polymorphisms with nephropathy in type 2 diabetes. We examined these polymorphisms in a case-control study of type 2 diabetic patients including 374 with DN and 392 without DN. LPL 447X-containing genotypes (447X+) were significantly decreased in DN patients [18.6 vs 25.6%, odds ratio (OR) = 0.66, p = 0.02], as were APOE epsilon3/epsilon3 genotypes (64.8 vs 73.1%, OR = 0.68, p = 0.01). In addition, combinations of genotypes [APOE epsilon3/epsilon3 and LPL 447X+ (OR = 0.56), APOC3 CC and LPL 447X+ (OR = 0.31), APOE epsilon3/epsilon3 and APOC3 CC (OR = 0.61] were protective for DN compared with the most common combination of the respective polymorphisms. Our findings suggest the importance of interactions among lipid genes in modulating the risk of DN.
No takes yet. Share an insight, caveat, or question.
Ng et al. (2006) conducted a case-control in Diabetic nephropathy in type 2 diabetes (n=766). LPL 447X-containing genotypes vs. Absence of LPL 447X-containing genotypes was evaluated on Diabetic nephropathy (OR 0.66, p=0.02). LPL 447X-containing genotypes and APOE epsilon3/epsilon3 genotypes were associated with a reduced risk of diabetic nephropathy in type 2 diabetes (OR 0.66, p=0.02 and OR 0.68, p=0.01, respectively).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: